Benzinga•2026-04-18
Apple Scores Key Win As Trade Commission Rejects Masimo's Bid To Reinstate Apple Watch Import BanMASI — Masimo Corp
NASDAQ · Health Care · Health Care
$178.71+29.18%Market cap9.32B
- Latest Close
- $178.71
- 30-Day Move
- +29.2%
- Market Cap
- $9.3B
- Shares Outstanding
- 52,200,000
- P/B Ratio
- 9.98
- ROE
- -21.0%
Analyst consensus: Buy · 15 analysts
NASDAQ:MASIHealth Care / Health CareDelayed public snapshot
Masimo Corp
A read-only Alphactor snapshot forMasimo Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$178.71
30-Day Move
+29.2%
Market Cap
$9.3B
Shares Outstanding
52,200,000
P/B Ratio
9.98
ROE
-21.0%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$178.71
+29.2%last 90 delayed daily bars
Market cap$9.3B
90D High
$179.00
90D Low
$125.94
Avg Volume
1,357,448
What stands out
Gross margin is running at 61.9%, which gives a quick read on operating quality before you open the full model.
Net margin is -9.9%, useful for comparing MASI against peers in Health Care.
MASI is up 29.2% over the last 30 trading days shown on this page.
Latest operating income is $84M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$62.55
Rule of 40
22.1%
Dark Pool Short %
57.0%
Fundamentals snapshot
Latest Close
$178.71
30-Day Move
+29.2%
Market Cap
$9.3B
Shares Outstanding
52,200,000
P/B Ratio
9.98
ROE
-21.0%
ROA
-8.9%
Gross Margin
61.9%
Operating Margin
20.3%
Net Margin
-9.9%
Debt / Equity
0.73
Current Ratio
2.49
Latest Revenue
$413M
Financial statement snapshot
Revenue
$413M
Gross Profit
$247M
Operating Income
$84M
Net Income
$68M
Gross Margin
6190.0%
Net Margin
-992.0%
Current Ratio
2.49
Debt / Equity
0.73
Valuation snapshot
Fair Value
$62.55
Upside / Downside
-65.0%
Signal
Overvalued
Implied Growth
18.6%
DCF
$25.03
EPV
$24.15
EV/Rev
$138.46
Growth Assumption
-9.1%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$193M
Valuation spread
Current Price
$178.71
Composite Fair Value
$62.55
DCF
$25.03
EPV
$24.15
EV/Rev
$138.46
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Quality snapshot
Altman Z
8.72
Safe
Piotroski
7
Strong (7-9)
Cash Conversion
-1.44x
Rule of 40
22.1%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $2.0B | $210M | $144M | $-27M |
| 2023-12-31 | $1.3B | $184M | $82M | $32M |
| 2024-12-31 | $1.4B | $64M | $-305M | $158M |
| 2025-12-31 | $1.5B | $313M | $-152M | $193M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$468,500
Sell Value
$4M
Buys
3
Sells
6
Buy Value
$468,500
Sell Value
$4M
Buy/Sell Ratio
0.50x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-12 | Koffey Quentin | J | 130,869 | $0.00 |
| 2026-03-11 | Young Micah W | M | 873 | $0.00 |
| 2026-03-11 | Young Micah W | F | 471 | $175.47 |
| 2026-03-11 | Young Micah W | M | 873 | $0.00 |
| 2026-03-11 | Szyman Catherine M. | M | 2,101 | $0.00 |
| 2026-03-11 | Szyman Catherine M. | F | 1,069 | $175.47 |
| 2026-03-11 | Szyman Catherine M. | M | 2,101 | $0.00 |
| 2026-03-11 | Koffey Quentin | J | 142,681 | $0.00 |
Institutional holders snapshot
Two Sigma Advisers
Filed 2025-05-15
--
--
BlackRock
Filed 2024-08-13
$1.2B
--
FMR LLC (Fidelity)
Filed 2026-02-17
$1.0B
-4.3%
Vanguard Group
Filed 2025-08-11
$780M
+1.2%
Capital Research Global Investors
Filed 2025-05-12
$343M
--
Geode Capital Management
Filed 2025-08-08
$151M
+6.2%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
3.53
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
15
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.